<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161566">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02063295</url>
  </required_header>
  <id_info>
    <org_study_id>ZAF-221</org_study_id>
    <nct_id>NCT02063295</nct_id>
  </id_info>
  <brief_title>An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury</brief_title>
  <official_title>Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zafgen, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zafgen, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of
      beloranib in obese subjects with hypothalamic injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in body weight from baseline to the end of the randomized dosing period.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lipid profile (cholesterol, LDL, HDL, triglycerides) from baseline to the end of the randomized dosing period</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hs-CRP from baseline to the end of the randomized dosing period.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hunger from baseline to the end of the randomized dosing period.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life from baseline to the end of the randomized dosing period.</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Obesity</condition>
  <condition>Over-weight</condition>
  <condition>Hypothalamic Injury</condition>
  <condition>Craniopharyngioma</condition>
  <arm_group>
    <arm_group_label>ZGN-440 sterile diluent</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo twice weekly subcutaneous injections for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ZGN-440 for injectable suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive ZGN-440 for injectable suspension (beloranib) twice weekly subcutaneous injections for up to 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZGN-440 sterile diluent</intervention_name>
    <description>ZGN-440 sterile diluent/placebo</description>
    <arm_group_label>ZGN-440 sterile diluent</arm_group_label>
    <other_name>ZGN-440 sterile diluent</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZGN-440 for injectable suspension</intervention_name>
    <arm_group_label>ZGN-440 for injectable suspension</arm_group_label>
    <other_name>ZGN-440 for injectable suspension</other_name>
    <other_name>ZGN-440</other_name>
    <other_name>Beloranib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obesity as a consequence of acquired anatomical hypothalamic damage as evidenced by
             BMI ≥30 and ≤60 kg/m2

          -  Greater than 6 months post-treatment, including chemotherapy, surgery or radiation
             with resulting injury to the hypothalamus and/or the pituitary

          -  Stable body weight for at least 3 months

          -  Type 2 diabetes mellitus is allowed

        Exclusion Criteria:

          -  Males taking gonadotropin replacement therapy (LH/FSH)

          -  Subjects who are planning any fertility treatment within 6 months of study
             participation

          -  Use of weight loss agents, including herbal medications, in the past 3 months

          -  Current or anticipated chronic use of narcotics or opiates

          -  History of severe psychiatric disorders

          -  Type 1 diabetes mellitus

          -  Metabolic disorders or genetic disorders linked to obesity

          -  History of any bariatric surgery

          -  Participation in any clinical study with an investigational drug or device within the
             3 months prior to enrollment in this study

          -  Blood loss or donation &gt;500 mL within the past 3 months

          -  Females who are pregnant, nursing, intend to become pregnant during the study or any
             males who plan to father/conceive a child within 6 months after completion of study
             participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Benoit</last_name>
      <phone>651-220-6254</phone>
      <email>christine.benoit@childrensmn.org</email>
    </contact>
    <investigator>
      <last_name>Jennifer Abuzzahab, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margo Black</last_name>
      <phone>615-936-8638</phone>
      <email>margo.black@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Ashley Shoemaker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Boden Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Fuller</last_name>
      <phone>+61 2 9036 3468</phone>
      <email>nick.fuller@sydney.edu.au</email>
    </contact>
    <investigator>
      <last_name>Tania Markovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Health, Metabolic Disorders Centre</name>
      <address>
        <city>Heidelberg Heights</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Purcell</last_name>
      <phone>+61 3 94964025</phone>
      <email>purcellk@unimelb.edu.au</email>
    </contact>
    <investigator>
      <last_name>Joseph Proietto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>February 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beloranib</keyword>
  <keyword>ZGN-440</keyword>
  <keyword>ZGN-440 for injectable suspension</keyword>
  <keyword>ZGN-433</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Craniopharyngioma</mesh_term>
    <mesh_term>Adamantinoma</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
